Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The present study investigated the effects of the selective neurokinin-2 (NK2) receptor antagonist SR48968 in behavioral, electrophysiological, and biochemical tests sensitive to the action of prototypical antidepressants (fluoxetine, imipramine) or to corticotropin-releasing factor (CRF) receptor antagonists, which have been proposed recently as potential antidepressants. Results showed that SR48968 (0.3-10 mg/kg i.p.) produced antidepressant-like activity because it reduced immobility in the forced swimming test in both mice and rats, and decreased the amount of maternal separation-induced vocalizations in guinea pig pups. This latter effect appears to involve a reduction of stress-induced substance P release because SR48968 reduced the separation-induced increase in the number of neurons displaying neurokinin-1 receptor internalization in the amygdala. Furthermore, SR48968 increased the expression of the cAMP response-element binding protein mRNA in the rat hippocampus after repeated (1 mg/kg i.p., 21 days), but not acute administration. Finally, neuronal firing of the locus coeruleus (LC) and noradrenergic (NE) release in the prefrontal cortex both elicited by an uncontrollable stressor or an intraventricular administration of CRF were reduced by SR48968 (0.3-1 mg/kg i.p.). The finding that SR48968 (1 mg/kg i.p.) blocked the cortical release of NE induced by an intra-LC infusion of the preferential NK2 receptor agonist neurokinin A suggested the presence of NK2 receptors in this latter region. Importantly, SR48965 (1-10 mg/kg i.p.), the optical antipode of SR48968, which is devoid of affinity for the NK2 receptor, was inactive in all the models used. These data suggest that NK2 receptor blockade may constitute a novel mechanism in the treatment of depression and CRF-related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Corticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · cited 1×
“…major involvement of brain noradrenergic (NE) systems in stress-related disorders, and the ability of CRF to activate these neuronal populations (Koob, 1999), the second part of this study explored the role of NK2 receptor activation in mediating CRF-induced firing of the locus coeruleus (LC)…”
Sánchez, C., & Meier, E. (1997) · Psychopharmacology · doi:10.1007/s002130050181 · Cited by 255
Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., Licinio, J., Wong, M.-L., Chrousos, G. P., Webster, E., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6415 · Cited by 242
Hahn, M. K., & Bannon, M. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00319-x · Cited by 90
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Neuroendocrine pharmacology of stress
Carrasco, G. A., & Van de Kar, L. D. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01285-8 · Cited by 914
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 403
Self-citationThe Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295
Self-citation
Metadata
- Authors
- Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Le Fur, G., & Soubrié, P.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 299
- Issue
- 2
- Pages
- 449-458
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2293895349
- Cited by
- 89
- References
- 5
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29250-8
- The paper
- Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Le Fur, G., & Soubrié, P. (2001). Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29250-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.